Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Rare & genetic · 2024

Xolremdi (mavorixafor)

The FDA approved Xolremdi (mavorixafor) on April 26, 2024 to treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).
Brand name
Xolremdi
Generic name
mavorixafor
FDA approval date
April 26, 2024
Approved use (FDA wording)
To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
Company
X4 Pharms
Application
NDA218709
Dosage form / route
CAPSULE · ORAL
Drug class (EPC)
CXC Chemokine Receptor 4 Antagonist [EPC]
Boxed warning on label
Not listed
Category on this site
Rare & genetic

Indications and usage, from the FDA label

XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. XOLREMDI is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.